Dr. Coleman has 18 years of experience in the pharmaceutical, biotechnology and complex generics industries with biologics and small molecules across a broad range of disease areas. She most recently served as Vice President and Head of Program Management at Theseus Pharmaceuticals focusing on pan variant KIT inhibitors for GIST and EGFR-mutant NSCLC. Prior to that she served as Executive Director, Head of Program Management at Allena Pharmaceuticals where she managed cross functional program teams through preclinical, Phase 1, Phase 2, and Phase 3 studies for difficult to treat metabolic diseases. From 2006 through 2018, Dr. Coleman held positions of increasing responsibility at Momenta Pharmaceuticals including, Director of Program & Alliance Management, Program leader and CMC team leader for multiple biosimilar programs across numerous indications. She holds a Ph.D. in Organic Chemistry from University College Dublin, Ireland and completed a Postdoctoral Fellowship in Organic Chemistry at the University of Pittsburgh.